睿知中国疾病研究地图
候选清单0

石家庄河北医科大学

河北医科大学第四医院

Fourth Hospital of Hebei Medical University

在本站收录的 53 种疾病中,这家医院列在其中 11 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

河北医科大学第四医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma123 篇牵头论文牵头 11 项开放试验
  2. 肝细胞癌Hepatocellular carcinoma20 篇牵头论文牵头 1 项开放试验
  3. 胃癌Stomach cancer104 篇牵头论文牵头 7 项开放试验
  4. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  5. 骨肉瘤Osteosarcoma6 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour7 篇牵头论文
  7. 多发性骨髓瘤Multiple myeloma4 篇牵头论文
  8. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  9. 重症肌无力Myasthenia gravis2 篇牵头论文
  10. 白塞病Behçet disease0 篇牵头论文
  11. IgA 肾病IgA nephropathy1 篇牵头论文

未列出的收录疾病:鼻咽癌、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 123 篇,占 4.2%。

牵头论文
123
2021–2025 年
牵头试验
17
任何状态,ClinicalTrials.gov
牵头的开放试验
11
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 202020212022: 313120222023: 232320232024: 202020242025: 27272025

石家庄有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 13

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
    分期
    II期
    开始
    2025-09
    登记号
    NCT07266480

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  2. 正在招募
    The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2025-09
    登记号
    NCT07290010

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  3. 正在招募
    Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-04
    登记号
    NCT06646588

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  4. 正在招募
    Minimally Residual of Esophageal Cancer 001
    分期
    未注明
    开始
    2023-02
    登记号
    NCT05952661

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  5. 正在招募
    Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2019-04
    登记号
    NCT03964753

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  6. 即将招募
    Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
    分期
    I期
    开始
    2026-07
    登记号
    NCT07697040

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  7. 即将招募
    Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-09
    登记号
    NCT07799077

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  8. 即将招募
    Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-10
    登记号
    NCT07823270

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  9. 即将招募
    Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
    分期
    II期
    开始
    2025-04
    登记号
    NCT06903871

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  10. 即将招募
    A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
    分期
    II期
    开始
    2025-08
    登记号
    NCT07112833

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  11. 即将招募
    Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
    分期
    II期
    开始
    2024-11
    登记号
    NCT06681285

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  12. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春

  13. 正在招募
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    分期
    未注明
    开始
    2022-07
    登记号
    NCT05443841

    年龄未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 8 家列出的医院为研究中心上海、南通、合肥、天津、泰州、石家庄、西安、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗新辅助与综合治疗分子标志物与基因
论文中的科室放疗科病理/检验科肿瘤内科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文123
  1. Exploring the Link Between Stress-Induced Naive T-Cells and Esophageal Squamous Cell Carcinoma Risk: A Multi-Omics Investigation.2026Annals of surgical oncology免费全文
  2. The prognostic value of tumor deposits in esophageal squamous cell carcinoma: A propensity score matching study.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Radiomics to predict PNI in ESCC.2025Abdominal radiology (New York)免费全文
  4. TRIM21-Mediated K11-Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. The Kinesin Eg5 Inhibitor K858 Enhances Radiosensitivity in Esophageal Squamous Cell Carcinoma and Affects the Expression of Epithelial-mesenchymal Transition Related Markers: In vitro and In vivo Studies.2025Anti-cancer agents in medicinal chemistry
  6. Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma.2025BMC cancer免费全文
  7. KBU2046 exerts inhibition on chemokine gradient-mediated motility of esophageal squamous cell carcinoma through reducing integrin expression.2025Biochimica et biophysica acta. Molecular basis of disease
  8. Aberrant CircTMEM45A Facilitates Inflammatory Progression of Esophageal Squamous Cell Carcinoma through m5C-Mediated NLRP3 Activation.2025Cancer research
  9. Patterns of recurrence after esophagectomy following neoadjuvant immunochemotherapy in patients with thoracic esophageal squamous cell carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. The Knockdown of ACTL6A Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Modulating the Wnt/β-Catenin Signaling Pathway.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology免费全文
  11. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study.2025Frontiers in immunology免费全文
  12. Endoplasmic reticulum stress-induced CRELD2 promotes APMAP-mediated activation of TGF-β/SMAD and NF-κB pathways in esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  13. Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT02025Frontiers in immunology免费全文
  14. Nomogram-based risk stratification to analyze the value of receiving postoperative adjuvant therapy after neoadjuvant immunochemotherapy for patients with locally advanced esophageal squamous carcinoma.2025Frontiers in immunology免费全文
  15. Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment.2025Frontiers in immunology免费全文
  16. Triptonide suppresses the FOXK1/AKT2 axis to reverse malignant phenotype and improve cisplatin efficacy in esophageal squamous cell carcinoma.2025Genes & genomics
  17. H-chain ferritin-based magnetic nanoparticles targeting CD71 for magnetic resonance imaging diagnosis of esophageal squamous cell carcinoma and its precancerous lesions.2025International journal of biological macromolecules
  18. CircPRKCA facilitates esophageal squamous cell carcinoma metastasis via m5C-dependent CSF2 mRNA stabilization.2025Journal of translational medicine免费全文
  19. NEK2 Promotes ESCC Malignant Progression by Inhibiting Cellular Senescence via the FOXM1/c-Myc/p27 Signaling Pathway.2025Molecular carcinogenesis
  20. Induction of CXCL8 by endoplasmic reticulum stress promotes migration and invasion of esophageal squamous cell carcinoma through activation of SMAD2/3.2025Molecular medicine reports免费全文
  21. Targeting tumor metabolism: The dual attack of emodin on glycolysis and oxidative phosphorylation in esophageal squamous cell carcinoma.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. The impact of radiation-related lymphocyte recovery on the prognosis of locally advanced esophageal squamous cell carcinoma patients: a retrospective analysis.2025Radiation oncology (London, England)免费全文
  23. Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma.2025Scientific reports免费全文
  24. Prognostic value of immunotrophic inflammatory markers in ESCC undergoing chemoradiotherapy combined with immunotherapy.2025Scientific reports免费全文
  25. The necroptosis-related lncRNA ENSG00000253385.1 promotes the progression of esophageal squamous cell carcinoma by targeting the miR-16-2-3p/VDAC1 axis.2025Scientific reports免费全文
  26. Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma.2025Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]免费全文
  27. IFI30 Knockdown Inhibits ESCC Progression by Promoting Apoptosis and Senescence via Activation of JNK and P21/P16 Pathways.2025Thoracic cancer免费全文
  28. E2F7 promotes ESCC progression and cisplatin resistance through transcriptional activation of DVL3 and the Wnt signaling pathway.2025World journal of surgical oncology免费全文
  29. Outcomes and predictive factors in post-surgical resection of sT4a esophageal cancer.2025World journal of surgical oncology免费全文
  30. Computed tomography radiomics identification of T1-2 and T3-4 stages of esophageal squamous cell carcinoma: two-dimensional or three-dimensional?2024Abdominal radiology (New York)免费全文
  31. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.2024BMC cancer免费全文
  32. Clinico-pathological study of esophageal mucoepidermoid carcinoma: a 10-year survival from a single center.2024BMC gastroenterology免费全文
  33. Prediction of lymphovascular invasion in esophageal squamous cell carcinoma by computed tomography-based radiomics analysis: 2D or 3D ?2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  34. CircJPH1 regulates the NF-κB/HERC5 axis to promote the malignant progression of esophageal squamous cell carcinoma through binding to XRCC6.2024Cellular signalling
  35. Long Non-coding RNA X-Inactive Specific Transcript Promotes Esophageal Squamous Cell Carcinoma Progression via the MicroRNA 34a/Zinc Finger E-box-Binding Homeobox 1 Pathway.2024Digestive diseases and sciences免费全文
  36. Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma.2024Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  37. FAM83D promotes the progression of 4NQO-induced esophageal carcinoma via inhibiting FBWX7.2024Experimental cell research
  38. SENP3 mediates the activation of the Wnt/β-catenin signaling pathway to accelerate the growth and metastasis of oesophagal squamous cell carcinoma in mice.2024Functional & integrative genomics
  39. Analysis of the incidence and mortality trends of esophageal cancer in cancer registry areas of China and Japan.2024International journal of cancer
  40. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.2024Journal of cancer research and clinical oncology免费全文
  41. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).2024Journal of cancer research and clinical oncology免费全文
  42. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  43. WTAP/CCND1 axis accelerates esophageal squamous cell carcinoma progression by MAPK signaling pathway.2024Neoplasma
  44. Periplcymarin targets glycolysis and mitochondrial oxidative phosphorylation of esophageal squamous cell carcinoma: Implication in anti-cancer therapy.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  45. SNHG6 facilitates the epithelial-mesenchymal transition and metastatic potential of esophageal squamous carcinoma through miR-26b-5p/ ITGB1 axis.2024Scientific reports免费全文
  46. Bacteroidetes promotes esophageal squamous carcinoma invasion and metastasis through LPS-mediated TLR4/Myd88/NF-κB pathway and inflammatory changes.2024Scientific reports免费全文
  47. Treatment-related pneumonitis after thoracic radiotherapy/chemoradiotherapy combined with anti-PD-1 monoclonal antibodies in advanced esophageal squamous cell carcinoma.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]免费全文
  48. LncRNA NONHSAT227443.1 Confers Esophageal Squamous Cell Carcinoma Chemotherapy Resistance by Activating PI3K/AKT Signaling via Targeting MRTFB.2024Technology in cancer research & treatment免费全文
  49. Ethanol exposure exacerbates 4-nitroquinoline-1-oxide induced esophageal carcinogenesis and induces invasive carcinoma with muscularis propria infiltration in a mouse model.2024Toxicology and applied pharmacology
  50. Mir-25 Promotes Metastasis of Esophageal Cancer by Targeting BTG2.2023Applied biochemistry and biotechnology
  51. A novel DNA damage repair gene-related prognostic model for evaluating the prognosis and tumor microenvironment infiltration of esophageal squamous cell carcinoma.2023BMC medical genomics免费全文
  52. CircRNA mannosidase alpha class 1A member 2 promotes esophageal squamous cell carcinoma progression by regulating C-C chemokine ligand 5.2023Biochemical and biophysical research communications
  53. Clinical Significance and Prognostic Value of the Expression of LAG-3 and FGL1 in Esophageal Squamous Cell Carcinoma.2023Bulletin of experimental biology and medicine
  54. RNA sequencing reveals the implication of the circRNA-associated ceRNA network in oesophageal squamous cell carcinoma.2023Carcinogenesis
  55. Reciprocal regulation of LINC00941 and SOX2 promotes progression of esophageal squamous cell carcinoma.2023Cell death & disease免费全文
  56. β-elemene Suppresses Migration of Esophageal Squamous Cell Carcinoma by Modulating Expression of MMP9 through the PI3K/Akt/NF-κB Pathway.2023Combinatorial chemistry & high throughput screening
  57. Clinical and Genomic Analysis of Patients with Short Survival after Surgery for Esophageal Squamous Cell Carcinoma.2023Digestive diseases (Basel, Switzerland)
  58. Methylation Mediated Downregulation of TOB1-AS1 and TOB1 Correlates with Malignant Progression and Poor Prognosis of Esophageal Squamous Cell Carcinoma.2023Digestive diseases and sciences
  59. Potential 'anti-cancer' effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells.2023European journal of medical research免费全文
  60. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospectiv2023Frontiers in immunology免费全文
  61. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.2023Frontiers in immunology免费全文
  62. P-Hydroxylcinnamaldehyde induces tumor-associated macrophage polarization toward the M1 type by regulating the proteome and inhibits ESCC in vivo and in vitro.2023International immunopharmacology
  63. Comparison of TNM AJCC/UICC 8th with JES 11th staging systems for prognostic prediction in patients with esophageal squamous cell carcinoma who underwent radical (chemo) radiotherapy in China.2023Journal of cancer research and therapeutics
  64. Circular RNA circ-TNRC6B inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by regulating the miR-452-5p/DAG1 axis.2023Molecular oncology免费全文
  65. Circular RNA hsa_circ_0002938 (circCRIM1) promotes the progression of esophageal squamous cell carcinoma by upregulating transcription factor 12.2023Neoplasma
  66. Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor.2023Oncology reports免费全文
  67. The host microbiota is associated with the occurrence and development of esophageal squamous cell carcinoma.2023Protein & cell免费全文
  68. Elective nodal irradiation versus involved-field irradiation for stage II-IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outc2023Radiation oncology (London, England)免费全文
  69. FOXK1 regulates malignant progression and radiosensitivity through direct transcriptional activation of CDC25A and CDK4 in esophageal squamous cell carcinoma.2023Scientific reports免费全文
  70. Effect of extracapsular lymph node involvement on the prognosis of patients with esophageal squamous cell carcinoma.2023Technology and health care : official journal of the European Society for Engineering and Medicine
  71. Tracheoesophageal fistula closure after staged dose-escalated radiotherapy for esophageal squamous cell carcinoma: a case report.2023The Journal of international medical research免费全文
  72. Bioinformatics and network pharmacology identify promotional effects and potential mechanisms of ethanol on esophageal squamous cell carcinoma and experimental validation.2023Toxicology and applied pharmacology
  73. MicroRNA-181a-5p prevents the progression of esophageal squamous cell carcinoma in vivo and in vitro via the MEK1-mediated ERK-MMP signaling pathway.2022Aging免费全文
  74. MDM4 polymorphisms associated with the risk but not the prognosis of esophageal cancer in Cixian high-incidence region from northern China.2022Asia-Pacific journal of clinical oncology
  75. Development and validation of a nomogram for prediction of cervical lymph node metastasis in middle and lower thoracic esophageal squamous cell carcinoma.2022BMC gastroenterology免费全文
  76. Can lymphovascular invasion be predicted by contrast-enhanced CT imaging features in patients with esophageal squamous cell carcinoma? A preliminary retrospective study.2022BMC medical imaging免费全文
  77. ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma.2022BioMed research international免费全文
  78. Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.2022Cancer biotherapy & radiopharmaceuticalsRCT
  79. SNHG17, as an EMT-related lncRNA, promotes the expression of c-Myc by binding to c-Jun in esophageal squamous cell carcinoma.2022Cancer science免费全文
  80. Long non-coding RNA NRSN2-AS1, transcribed by SOX2, promotes progression of esophageal squamous cell carcinoma by regulating the ubiquitin-degradation of PGK1.2022Clinical & experimental metastasis
  81. Downregulation of LINC00886 facilitates epithelial-mesenchymal transition through SIRT7/ELF3/miR-144 pathway in esophageal squamous cell carcinoma.2022Clinical & experimental metastasis
  82. Folate Receptor 4-Expressing T cell Is Associated with Disease-Free Survival in Patients with Esophageal Squamous Cell Carcinoma.2022Disease markers免费全文
  83. Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A.2022Drug design, development and therapy免费全文
  84. LncRNA GATA2-AS1 suppresses esophageal squamous cell carcinoma progression via the mir-940/PTPN12 axis.2022Experimental cell research
  85. CAF-derived exosomes deliver LINC01410 to promote epithelial-mesenchymal transition of esophageal squamous cell carcinoma.2022Experimental cell research
  86. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.2022Frontiers in immunology免费全文
  87. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.2022Frontiers in immunology免费全文
  88. Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma.2022Frontiers in immunology免费全文
  89. Irradiation-induced exosomal HMGB1 to confer radioresistance via the PI3K/AKT/FOXO3A signaling pathway in ESCC.2022Journal of translational medicine免费全文
  90. Recent advances in esophageal squamous cell precancerous conditions: A review.2022Medicine免费全文
  91. Novel nomograms predicting the survival of patients with nonsurgical thoracic esophageal squamous cell carcinoma treated with IMRT: A retrospective analysis.2022Medicine免费全文
  92. HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma.2022Molecular biology reports免费全文
  93. Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma.2022Molecular biology reports
  94. circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion.2022Molecular cancer免费全文
  95. Prognostic Significance of Prognostic Nutritional Index in Esophageal Squamous Cell Carcinoma Patients Undergoing Radical Radiotherapy: A Propensity Score Matching Analysis.2022Nutrition and cancer
  96. E2F1-activated NRSN2 promotes esophageal squamous cell carcinoma progression through AKT/mTOR pathway.2022Pathology, research and practice
  97. KTN1-AS1, a SOX2-mediated lncRNA, activates epithelial-mesenchymal transition process in esophageal squamous cell carcinoma.2022Scientific reports免费全文
  98. The circRNA circADAMTS6 promotes progression of ESCC and correlates with prognosis.2022Scientific reports免费全文
  99. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.2022Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]免费全文
  100. Effect of taking aspirin before diagnosis on the prognosis of esophageal squamous cell carcinoma and analysis of prognostic factors.2022The Journal of international medical research免费全文
  101. Is adjuvant immunotherapy a new standard for non-pathological complete response patients with resectable esophageal squamous cell carcinoma?2022Thoracic cancer免费全文
  102. Circ_0005231 promotes the progression of esophageal squamous cell carcinoma via sponging miR-383-5p and regulating KIAA0101.2022Thoracic cancer免费全文
  103. Could intracranial tumor volume predict prognosis of patients with brain metastases from esophageal carcinoma?2022Thoracic cancer免费全文
  104. Preliminary analysis of the benefits of different irradiation types on patients with postoperative locoregional recurrence of esophageal cell squamous carcinoma.2021Annals of palliative medicine
  105. Postoperative Adjuvant Therapy for Patients with pN+ Esophageal Squamous Cell Carcinoma.2021BioMed research international免费全文
  106. LncRNA DDX11 antisense RNA 1 promotes EMT process of esophageal squamous cell carcinoma by sponging miR-30d-5p to regulate SNAI1/ZEB2 expression and Wnt/β-catenin pathway.2021Bioengineered免费全文
  107. CDH1 Gene rs1801552 C/T Polymorphism Increases Susceptibility to Esophageal Squamous Cell Carcinoma but Not to Gastric Cardiac Adenocarcinoma.2021Cancer investigation
  108. ZEB1 represses biogenesis of circ-DOCK5 to facilitate metastasis in esophageal squamous cell carcinoma via a positive feedback loop with TGF-β.2021Cancer letters
  109. MTA2 promotes the metastasis of esophageal squamous cell carcinoma via EIF4E-Twist feedback loop.2021Cancer science免费全文
  110. SNHG5 inhibits the progression of EMT through the ubiquitin-degradation of MTA2 in oesophageal cancer.2021Carcinogenesis
  111. Long noncoding RNA DGCR5 involves in tumorigenesis of esophageal squamous cell carcinoma via SRSF1-mediated alternative splicing of Mcl-1.2021Cell death & disease免费全文
  112. Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing.2021Chinese medical journal免费全文
  113. TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression.2021Environmental and molecular mutagenesis
  114. HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2.2021Experimental cell research
  115. SNORA42 promotes oesophageal squamous cell carcinoma development through triggering the DHX9/p65 axis.2021Genomics
  116. Survival risk prediction model for patients with pT1-3 N0M0 esophageal squamous cell carcinoma after R0 esophagectomy with two-field lymphadenectomy for therapeutic purposes.2021Journal of cardiothoracic surgery免费全文
  117. Long non-coding RNA SPRY4-IT1 as a promising indicator for three field lymph-node dissection of thoracic esophageal carcinoma.2021Journal of cardiothoracic surgery免费全文
  118. Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study.2021Medicine免费全文
  119. Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin.2021Molecular cancer免费全文
  120. LINC00239 Interacts with C-Myc Promoter-Binding Protein-1 (MBP-1) to Promote Expression of C-Myc in Esophageal Squamous Cell Carcinoma.2021Molecular cancer research : MCR
  121. FOXD3 suppresses epithelial-mesenchymal transition through direct transcriptional promotion of SMAD7 in esophageal squamous cell carcinoma.2021Molecular carcinogenesis
  122. MicroRNA‑485‑5p suppresses the progression of esophageal squamous cell carcinoma by targeting flotillin‑1 and inhibits the epithelial‑mesenchymal transition.2021Oncology reports免费全文
  123. MicroRNA-29b regulates the radiosensitivity of esophageal squamous cell carcinoma by regulating the BTG2-mediated cell cycle.2021Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
中文论文(未计入)4
  1. [LINC00261 suppresses esophageal squamous cell carcinoma proliferation, invasion, and metastasis by targeting the miR-23a-3p/ZNF292 axis].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  2. [Efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [MiR-1-3p inhibits mitophagy in esophageal squamous cell carcinoma by targeting SLC7A11].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Prognostic analysis of different comprehensive treatment models for locally advanced esophageal squamous cell carcinoma based on propensity score matching].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
它在 ClinicalTrials.gov 上的全部试验(任何状态)24
  1. Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC即将招募NCT07697040牵头方I期2026-07 启动
  2. Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma即将招募NCT07823270牵头方II期2026-10 启动
  3. Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma即将招募NCT07799077牵头方II期2026-09 启动
  4. Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)即将招募NCT06903871牵头方II期2025-04 启动
  5. Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.正在招募NCT07266480牵头方II期2025-09 启动
  6. A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)即将招募NCT07112833牵头方II期2025-08 启动
  7. The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma正在招募NCT07290010牵头方II期2025-09 启动
  8. Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma正在招募NCT06646588牵头方II期2024-04 启动
  9. Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)即将招募NCT06681285牵头方II期2024-11 启动
  10. Minimally Residual of Esophageal Cancer 001正在招募NCT05952661牵头方2023-02 启动
  11. Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma正在招募NCT03964753牵头方II期2019-04 启动
  12. Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma状态不明NCT06103890牵头方2023-05 启动
  13. A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC状态不明NCT04286958牵头方II期2020-04 启动
  14. Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal Carcinoma状态不明NCT03900871牵头方早期I期2019-04 启动
  15. Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma(ChinECR)状态不明NCT06478355牵头方不分期2018-01 启动
  16. A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma已终止NCT03320629牵头方II期2017-11 启动
  17. The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC)进行中,不再招募NCT06828718牵头方2015-01 启动
  18. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  19. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)正在招募NCT05443841研究中心2022-07 启动
  20. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  21. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma已完成NCT04974047研究中心II期2021-08 启动
  22. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  23. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  24. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma状态不明NCT02409186研究中心III期2015-03 启动
PubMed 以外找到的论文(未计入)57
  1. 152. THE PROGNOSTIC IMPACT OF PARA-RECURRENT LARYNGEAL NERVE LYMPH NODE DISSECTION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE COHORT STUDY2025Diseases of the Esophagus论文
  2. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  3. 233eTiP Adebrelimab in the adjuvant treatment of esophageal squamous cell carcinoma: A randomized controlled clinical trial (PAIT-ESCC-0825)2025Immuno-Oncology Technology论文
  4. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagus论文
  5. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Research会议摘要
  6. Analysis of Treatment Patterns and Prognostic Factors in Patients with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma2025International Journal of Radiation Oncology*Biology*Physics论文
  7. Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial.2025Journal of Clinical Oncology会议摘要
  8. Effect of fusobacterium nucleatum on NF-κB/HIF-1α/CCL20 pathway and M2 macrophages infiltration in esophageal squamous cell carcinoma.2025Journal of Clinical Oncology会议摘要
  9. Efficacy and Safety of Neoadjuvant Therapies in Locally Advanced Esophageal Squamous Cell Carcinoma: A Comprehensive Retrospective Analysis2025International Journal of Radiation Oncology*Biology*Physics论文
  10. Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.2025Journal of Clinical Oncology会议摘要
  11. Potential role of CCND1 in neoadjuvant therapy efficacy in esophageal squamous cell carcinoma and its relation to extracellular matrix.2025Journal of Clinical Oncology论文
  12. Regulation of tumor-associated fibroblasts by TACSTD2 in esophageal squamous cell carcinoma and its potential role in immunotherapy resistance.2025Journal of Clinical Oncology论文
  13. Study on DLGAP5 and MELK as potential biomarkers in esophageal squamous cell carcinoma2025Research Square预印本
  14. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncology会议摘要
  15. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncology撤稿
  16. A zinc oxide–tin oxide–nerolidol hybrid nanomaterial: Efficacy against esophageal squamous cell carcinoma2024Open Chemistry论文
  17. Efficacy and Safety of Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligorecurrence2024International Journal of Radiation Oncology*Biology*Physics论文
  18. FOXD1 promotes proliferation, migration, and epithelial-mesenchymal transformation in esophageal squamous cell carcinoma by targeting SNAI12024Process Biochemistry论文
  19. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  20. Fusobacterium nucleatum to promote esophageal squamous cell carcinoma progression via CCL20/CCR6-mediated migration of macrophages to the tumour micro environment.2024Journal of Clinical Oncology会议摘要
  21. Pathological Response and Survival Outcome after Neoadjuvant Chemoradiotherapy vs. Immunochemotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physics论文
  22. Patterns of recurrence after esophagectomy following neoadjuvant Immunochemotherapy for esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  23. Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligometastasis at Initial Diagnosis2024International Journal of Radiation Oncology*Biology*Physics论文
  24. The clinical significance and expression of MAGE-A3 in patients with esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  25. The clinical significance of PRMT8 expression in esophageal squamous cell carcinoma and the influence on prognosis.2024Journal of Clinical Oncology会议摘要
  26. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncology会议摘要
  27. Tumor Immune Microenvironment Remodeling and Prognosis of Patients with Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy with and without Immunotherapy2024International Journal of Radiation Oncology*Biology*Physics论文
  28. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncology论文
  29. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncology论文
  30. Elective Nodal Irradiation vs. Involved-Field Irradiation for Stage Ⅱ-Ⅳ Cervical Esophageal Squamous Cell Carcinoma Patients Undergoing Definitive Concurrent Chemoradiotherapy: A Retrospective Propensity Study with Eight-Year Survival Outco2023International Journal of Radiation Oncology*Biology*Physics论文
  31. Meta-analysis of the efficacy and toxicity of paclitaxel combined with platinum (PTX) and fluorouracil combined with cisplatin (PF) in the treatment of concurrent chemoradiotherapy (CCRT) for unresectable esophageal cancer2023Research Square预印本
  32. SF3B4 Regulated Alternative Splicing that Produced an Oncogenic Isoform of HOXA11-AS to Promote Glycolytic Reprogramming and ESCC Progression2023Research Square预印本
  33. The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma.2023Journal of Clinical Oncology会议摘要
  34. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncology论文
  35. 1234P Neoadjuvant camrelizumab plus docetaxel and carboplatin in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective study2022Annals of Oncology论文
  36. 1262TiP Efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer2022Annals of Oncology论文
  37. A randomized, controlled, multicenter study of nab-paclitaxel plus cisplatin followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma (ESCC).2022Journal of Clinical Oncology会议摘要
  38. Additional file 1 of Development and validation of a nomogram for prediction of cervical lymph node metastasis in middle and lower thoracic esophageal squamous cell carcinoma2022Figshare数据集
  39. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  40. Expression of FGL1, Distribution of Tumor-Infiltrating Lymphocytes, and Their Clinical Significance in Esophageal Squamous-Cell Carcinoma2022DOAJ (DOAJ: Directory of Open Access Journals)论文
  41. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  42. Risk Factors of Treatment-Related Pneumonitis after Thoracic Radiotherapy/Chemoradiotherapy Combined with Anti-PD-1 mAb in Esophageal Squamous Cell Carcinoma2022International Journal of Radiation Oncology*Biology*Physics论文
  43. SRSF1 promotes proliferation, invasion and migration of esophageal squamous cell carcinoma Eca9706 cells by regulating VEGFA mRNA alternative splicing2022DOAJ (DOAJ: Directory of Open Access Journals)论文
  44. The microbial characteristics of patients with esophageal squamous cell carcinoma after chemotherapy and after immunotherapy.2022Journal of Clinical Oncology会议摘要
  45. 110P Neoadjuvant PD-1 blockade combined with chemotherapy for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC): A real world data analysis2021Annals of Oncology论文
  46. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncology论文
  47. 557 Neoadjuvant Camrelizumab in combination with albumin paclitaxel and cisplatin for patients with locally advanced esophageal squamous cell carcinoma (ESCC)2021Journal for ImmunoTherapy of Cancer会议摘要
  48. 978P A prospective study of camrelizumab monotherapy following definitive concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell cancer2021Annals of Oncology论文
  49. A Nomogram Model Based on Enhanced CT Radiomics Features for Predicting Tumor Response to Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma2021Research Square预印本
  50. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis2021International Journal of Radiation Oncology*Biology*Physics论文
  51. Camrelizumab combined with albumin paclitaxel and cisplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  52. Corrigendum: Contrast-Enhanced CT-Based Radiomics Analysis in Predicting Lymphovascular Invasion in Esophageal Squamous Cell Carcinoma2021Frontiers in Oncology勘误
  53. Exosome Releasing HSPD1 Assists HNF1A in Regulating the Invasion Ability and Radiosensitivity of Esophageal Squamous Cell Carcinoma Cells via Activating EMT2021Research Square预印本
  54. Expression of LncRNA DLEU1 in Esophageal Squamous Cell Carcinoma and Its Effect on Proliferation and Migration of ESCC Cells2021DOAJ (DOAJ: Directory of Open Access Journals)论文
  55. Impact and Analysis of Prognostic Factors in Patients with Non-Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Single Institution Study2021Open Journal of Internal Medicine论文
  56. Radiotherapy for Esophageal Squamous Cell Carcinoma Concomitant With Hypoproteinemia: a Case Report2021未列出期刊预印本
  57. The microbial characteristics of patients with esophageal squamous cell carcinoma before and after immunotherapy.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.1%。

牵头论文
20
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 6620222023: 3320232024: 3320242025: 552025

石家庄有 4 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-03
    登记号
    NCT07179900

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  2. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  3. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物局部治疗(消融、TACE、HAIC)
论文中的科室普外/肝胆胰外科消化/肝病科风湿免疫科肿瘤内科
牵头的论文20
  1. Estrogen receptor α suppresses hepatocellular carcinoma by restricting M2 macrophage infiltration through the YAP-CCL2 axis.2025BMC cancer免费全文
  2. Identification and validation of a lenvatinib resistance-related prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance.2025BMC gastroenterology免费全文
  3. Role of CD28+ PD-1+ Tc cells in immune response and prognosis prediction in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  4. CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration.2025PeerJ免费全文
  5. Hypoxia-activated oxidative stress mediates SHP2/PI3K signaling pathway to promote hepatocellular carcinoma growth and metastasis.2025Scientific reports免费全文
  6. G-CSF promotes the development of hepatocellular carcinoma by activating the PI3K/AKT/mTOR pathway in TAM.2024Aging免费全文
  7. Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: a population-based study.2024BMC gastroenterology免费全文
  8. The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients.2024Frontiers in immunology免费全文
  9. Role of TOP2A and CDC6 in liver cancer.2023Medicine免费全文
  10. Molecular docking and in vitro experiments verified that kaempferol induced apoptosis and inhibited human HepG2 cell proliferation by targeting BAX, CDK1, and JUN.2023Molecular and cellular biochemistry
  11. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.2023Technology in cancer research & treatment免费全文
  12. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma.2022BMC medical genomics免费全文
  13. GCSF as a Potential Molecular Target for Overall Survival of Hepatocellular Carcinoma.2022Combinatorial chemistry & high throughput screening
  14. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.2022Frontiers in endocrinology免费全文
  15. Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index.2022Future oncology (London, England)
  16. PRR34-AS1 promotes exosome secretion of VEGF and TGF-β via recruiting DDX3X to stabilize Rab27a mRNA in hepatocellular carcinoma.2022Journal of translational medicine免费全文
  17. Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.2022PloS one免费全文
  18. Hydrazinocurcumin Induces Apoptosis of Hepatocellular Carcinoma Cells Through the p38 MAPK Pathway.2021Clinical and translational science免费全文
  19. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.2021Frontiers in immunology免费全文
  20. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.2021Recent patents on anti-cancer drug discovery
中文论文(未计入)1
  1. [HDAC2-mediated H3K27 acetylation promotes the proliferation and migration of hepatocellular carcinoma cells].2025Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma正在招募NCT07179900牵头方II期2025-03 启动
  2. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  4. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  5. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 104 篇,占 1.1%。

牵头论文
104
2021–2025 年
牵头试验
17
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
11
由其他机构牵头
每年牵头的论文数
2021: 202020212022: 151520222023: 191920232024: 262620242025: 23232025

石家庄有 5 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 18

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
    分期
    未注明
    开始
    2026-03
    登记号
    NCT07401173

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  2. 正在招募
    Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07849608

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  3. 正在招募
    Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer
    分期
    未注明
    开始
    2025-01
    登记号
    NCT07124754

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  4. 正在招募
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
    分期
    II期
    开始
    2025-09
    登记号
    NCT07289997

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河北医科大学第四医院石家庄

  5. 即将招募
    A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
    分期
    II期
    开始
    2025-12
    登记号
    NCT07304258

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  6. 邀请入组
    Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients
    分期
    未注明
    开始
    2025-01
    登记号
    NCT06947096

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  7. 邀请入组
    AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data
    分期
    未注明
    开始
    2025-01
    登记号
    NCT06957678

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:河北医科大学第四医院石家庄

  8. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  9. 正在招募
    Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
    分期
    未注明
    开始
    2026-02
    登记号
    NCT07401199

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心武汉、石家庄

  10. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川

  11. 正在招募
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    分期
    III期
    开始
    2025-08
    登记号
    NCT07023315

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、哈尔滨、石家庄、福州

  12. 正在招募
    A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
    分期
    II期
    开始
    2025-08
    登记号
    NCT07110571

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心杭州、石家庄

  13. 正在招募
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    分期
    II期
    开始
    2025-12
    登记号
    NCT07127822

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院;另有 8 家列出的医院为研究中心北京、哈尔滨、天津、太原、成都、石家庄、西安、郑州、青岛

  14. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  15. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  16. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

  17. 即将招募
    Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07828899

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:温州医科大学附属第一医院;另有 2 家列出的医院为研究中心济南、温州、石家庄

  18. 即将招募
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07902596

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 6 家列出的医院为研究中心上海、南京、石家庄、苏州、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期影像与人工智能手术
论文中的科室消化/肝病科风湿免疫科影像/核医学科肿瘤内科
牵头的论文104
  1. Safety and feasibility of robot-assisted remote radical gastrectomy for gastric cancer based on 5G communication technology (FUTURE-04): a prospective, single-arm clinical trial.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  2. Interpretable Multimodal Fusion Model Enhances Postoperative Recurrence Prediction in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Multimodal Artificial Intelligence-Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology-Positive Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Diagnostic value of the cardiophrenic lymph nodes in gastric peritoneum metastases.2025African health sciences免费全文
  5. Safety and short‑term outcomes of a modified tubular esophagogastrostomy versus double tract reconstruction after proximal gastrectomy: a propensity score matching analysis.2025BMC cancer免费全文
  6. Association of low skeletal muscle mass and radiodensity with clinical outcomes in patients undergoing robotic radical gastric cancer surgery: a population-based retrospective cohort study.2025BMC cancer免费全文
  7. Preoperative sarcopenia and postoperative accelerated muscle loss negatively impact survival after resection of locally advanced gastric cancer.2025BMC cancer免费全文
  8. Radiomics-based ensemble model predicts postoperative recurrence of gastric cancer.2025BMC medicine免费全文
  9. Safety and efficacy of the Toumai robotic assisted versus the DaVinci robotic assisted radical gastrectomy for patients with gastric cancer.2025BMC surgery免费全文
  10. Comparative clinical efficacy of hybrid EMR-hot avulsion versus thermal ablation for post-ESD residual margins (≤ 1 cm) in early gastric cancer: a preliminary study.2025BMC surgery免费全文
  11. SphK2 promotes the progression of Helicobacter pylori-positive gastric cancer by regulating the Ras/MEK/ERK pathway.2025Biochemical and biophysical research communications
  12. Identification of Anoikis-Related Genes in Gastric Cancer: Bioinformatics and Experimental Validation.2025Cancer medicine免费全文
  13. Immunohistochemical-Based Molecular Typing of ACRG Combined With Immune-Associated PD-L1 Expression Can Predict the Prognosis of Gastric Cancer.2025Cancer medicine免费全文
  14. Huopuxialing Decoction: A Promising Candidate for Precancerous Lesions of Gastric Cancer Treatment Based on Bioinformatics and Experimental Verification.2025Combinatorial chemistry & high throughput screening
  15. Concomitant gastric cancer and neuroendocrine tumours in the stomach: a rare case series of 3 patients and a literature review.2025Diagnostic pathology免费全文
  16. Subcutaneous adipose tissue [18F]FDG uptake and CT-derived body composition variables for predicting survival outcomes in patients with locally advanced gastric cancer.2025European journal of nuclear medicine and molecular imaging
  17. Efficacy of traditional Chinese medicine in the conservative management of complete small intestinal obstruction post-gastric cancer surgery: A case report.2025Explore (New York, N.Y.)
  18. Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment.2025Frontiers in immunology免费全文
  19. Preoperative liquid biopsy transcriptomic panel for risk assessment of lymph node metastasis in T1 gastric cancer.2025Journal of experimental & clinical cancer research : CR免费全文
  20. Lymph node metastasis mapping and prognostic analysis of early gastric cancer.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  21. Comparative genomic analysis unveiling the mutational landscape associated with premalignant lesions and early-stage gastric cardia cancer.2025Medicine免费全文
  22. Huo Po Xia Ling decoction exerts preventive and improvement effects on gastric precancerous lesions by remodeling gut microbiota and associated metabolites.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  23. Lian Qiao Wen Dan Decoction attenuates gastric carcinogenesis by alleviating oxidative phosphorylation dysfunction.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  24. FDP/FIB ratio serves as a novel biomarker for diagnosing bone marrow invasion in gastric cancer and predicting patient prognosis\.2025Scientific reports免费全文
  25. Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients.2024Abdominal radiology (New York)免费全文
  26. Clinical calculator based on CT and clinicopathologic characteristics predicts short-term prognosis following resection of microsatellite-stabilized diffuse gastric cancer.2024Abdominal radiology (New York)
  27. Transcriptomics-Based Liquid Biopsy for Early Detection of Recurrence in Locally Advanced Gastric Cancer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  28. LncRNA HAGLR regulates gastric cancer progression by regulating the miR-20a-5p/E2F1 axis.2024Aging免费全文
  29. Endoscopic submucosal dissection in a patient with gastric submucosal parasitic granuloma.2024Asian journal of surgery
  30. Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer.2024BMC cancer免费全文
  31. Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study.2024BMC cancer免费全文
  32. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.2024BMC cancer免费全文
  33. Blood lipid profiles associated with metastatic sites in advanced gastric cancer.2024BMC gastroenterology免费全文
  34. Mapping spatial heterogeneity in gastric cancer microenvironment.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  35. Application of Intelligent Management Model Based on Electronic Patient-Reported Outcome During Immunotherapy in Patients with Gastric Cancer: A Single-Center Retrospective Study.2024British journal of hospital medicine (London, England : 2005)
  36. Effect of Personalized Nutrition Combined with Acceptance and Commitment Therapy on Psychological Resilience, Quality of Life and Side Effects of Chemotherapy in Patients with Advanced Gastric Cancer.2024British journal of hospital medicine (London, England : 2005)
  37. Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using 18F-FDG Positron Emission Tomography/Computed Tomography-Based Radiomics: A Pilot Study.2024Cancer biotherapy & radiopharmaceuticals
  38. BBOX1-AS1 promotes gastric cardia adenocarcinoma progression via interaction with CtBP2 to facilitate the epithelial-mesenchymal transition process.2024Cancer science免费全文
  39. Exploring the Pharmacological Mechanisms of P-hydroxylcinnamaldehyde for Treating Gastric Cancer: A Pharmacological Perspective with Experimental Confirmation.2024Current molecular pharmacology
  40. Myosteatosis predicts postoperative complications and long-term survival in robotic gastrectomy for gastric cancer: A propensity score analysis.2024European journal of clinical investigation
  41. The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment.2024Frontiers in immunology免费全文
  42. A retrospective analysis of lymph node dissection in Siewert II adenocarcinoma of the esophagogastric junction.2024Journal of cardiothoracic surgery免费全文
  43. Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer.2024Journal of experimental & clinical cancer research : CR免费全文
  44. Circ_0001947 encapsulated by small extracellular vesicles promotes gastric cancer progression and anti-PD-1 resistance by modulating CD8+ T cell exhaustion.2024Journal of nanobiotechnology免费全文
  45. MicroRNA-431-5p inhibits angiogenesis, lymphangiogenesis, and lymph node metastasis by affecting TGF-β1/SMAD2/3 signaling via ZEB1 in gastric cancer.2024Molecular carcinogenesis
  46. Comparison of 68 Ga-FAPI-04 PET/CT with 18 F-FDG PET/CT for diagnosis and staging of gastric and colorectal cancer.2024Nuclear medicine communications
  47. Impact of preoperative sarcopenia on postoperative complications and prognosis in patients undergoing robotic gastric cancer surgery: A propensity score matching study.2024Nutrition (Burbank, Los Angeles County, Calif.)
  48. N6-methyladenosine modified circPAK2 promotes lymph node metastasis via targeting IGF2BPs/VEGFA signaling in gastric cancer.2024Oncogene
  49. Data-independent acquisition combined with liquid chromatography mass spectrometry technique to detect prognostic protein markers in type I gastric neuroendocrine neoplasm.2024Rapid communications in mass spectrometry : RCM
  50. Gastric metastasis from breast cancer: five cases and a single-institutional review.2024The Journal of international medical research免费全文
  51. Can PD-L1 expression be predicted by contrast-enhanced CT in patients with gastric adenocarcinoma? a preliminary retrospective study.2023Abdominal radiology (New York)免费全文
  52. Construction of a nomogram model for predicting peritoneal metastasis in gastric cancer: focused on cardiophrenic angle lymph node features.2023Abdominal radiology (New York)免费全文
  53. M-CSF secreted by gastric cancer cells exacerbates the progression of gastric cancer by increasing the expression of SHP2 in tumor-associated macrophages.2023Aging免费全文
  54. Joint effect of THBS2 and VCAN accelerating the poor prognosis of gastric cancer.2023Aging免费全文
  55. Clinical implications of micro lymph node metastasis for patients with gastric cancer.2023BMC cancer免费全文
  56. Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  57. Effect of sevoflurane on CD4+CD25+FOXP3+ regulatory T cells in patients with gastric cancer undergoing radical surgery.2023Cellular and molecular biology (Noisy-le-Grand, France)
  58. Establishment and validation of a prognostic model for gastric cancer patients of Hebei Province in China.2023Chinese clinical oncology
  59. The inflammatory burden index: A promising prognostic predictor in patients with locally advanced gastric cancer.2023Clinical nutrition (Edinburgh, Scotland)
  60. Mechanisms and biomarkers of immune-related adverse events in gastric cancer.2023European journal of medical research免费全文
  61. Lymphangiogenesis in gastric cancer: function and mechanism.2023European journal of medical research免费全文
  62. Prediction of occult peritoneal metastases or positive cytology using CT in gastric cancer.2023European radiology
  63. Comparison of short-term efficacy and safety between total robotic and total 3D laparoscopic distal radical gastrectomy for gastric cancer in Enhanced Recovery After Surgery (ERAS) protocol: a propensity score matching study.2023Journal of robotic surgery免费全文
  64. Effect of Ward Noise Reduction Technology Combined with Music Therapy on Negative Emotions in Inpatients Undergoing Gastric Cancer Radiotherapy: A Retrospective Study.2023Noise & health免费全文
  65. Computed tomographic imaging features to differentiate gastric schwannomas from gastrointestinal stromal tumours: a matched case-control study.2023Scientific reports免费全文
  66. Identification of INHBA as a potential biomarker for gastric cancer through a comprehensive analysis.2023Scientific reports免费全文
  67. Safety and efficacy of robotic-assisted versus laparoscopic distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer.2023Surgical endoscopy
  68. The Regulatory Mechanism and Research Progress of Ferroptosis in Gastric Cancer.2023Technology in cancer research & treatment免费全文
  69. Computed tomography features of gastric leiomyoma versus gastric stromal tumor: a case-control study with propensity score matching.2023The Journal of international medical research免费全文
  70. Protein Phosphatase PPM1B Inhibits Gastric Cancer Progression and Serves as a Favorable Prognostic Biomarker.2022Applied immunohistochemistry & molecular morphology : AIMM
  71. Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?2022BMC cancer免费全文
  72. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilim2022BMC gastroenterology免费全文
  73. LINC01088 regulates the miR-95/LATS2 pathway through the ceRNA mechanism to inhibit the growth, invasion and migration of gastric cancer cells.2022International journal of immunopathology and pharmacology免费全文
  74. Research on the mechanisms of taraxerol for the treatment of gastric cancer effect based on network pharmacology.2022International journal of immunopathology and pharmacology免费全文
  75. Assessment of Carbon Nanoparticle Suspension Lymphography-Guided Distal Gastrectomy for Gastric Cancer.2022JAMA network open免费全文
  76. MZF1 Transcriptionally Activated MicroRNA-328-3p Suppresses the Malignancy of Stomach Adenocarcinoma via Inhibiting CD44.2022Journal of immunology research免费全文
  77. A Nomogram Model for Evaluating the Risk of Lymph Node Metastasis in cT2-cT4N0M0 Gastric Cancer Population.2022Medical science monitor : international medical journal of experimental and clinical research免费全文
  78. The phosphorylation level of Cofilin-1 is related to the pathological subtypes of gastric cancer.2022Medicine免费全文
  79. Diagnostic accuracy of gastric filling ultrasonography in preoperative invasion depth (T stage) of gastric cancer: Meta-analysis.2022Medicine免费全文
  80. Family history of malignant tumor is a predictor of gastric cancer prognosis: Incorporation into a nomogram.2022Medicine免费全文
  81. To investigate the prognostic factors of stage Ⅰ-Ⅱ gastric cancer based on P53 mutation and tumor budding.2022Pathology, research and practice
  82. Flotillin-1 promotes EMT of gastric cancer via stabilizing Snail.2022PeerJ免费全文
  83. Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer.2022Surgical endoscopy免费全文
  84. The benefits of surgery plus extensive intraoperative peritoneal lavage (EIPL) for patients with gastric cancer compared with surgery alone: a systematic review and meta-analysis.2022Updates in surgery
  85. Krüppel-like factor 1 serves as a facilitator in gastric cancer progression via activating the Wnt/β-catenin pathway.2021Acta biochimica Polonica
  86. Type I collagen promotes tumor progression of integrin β1 positive gastric cancer through a BCL9L/β-catenin signaling pathway.2021Aging免费全文
  87. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.2021BMC cancer免费全文
  88. Clinical significance of novel identified high-frequency tumor-specific peptides associated signature in predicting disease status of gastric cancer patients.2021BioFactors (Oxford, England)
  89. Advances in clinical immunotherapy for gastric cancer.2021Biochimica et biophysica acta. Reviews on cancer
  90. 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Metabolic Parameters Before and After Neoadjuvant Chemotherapy Can Predict the Postoperative Prognosis of Locally Advanced Gastric Cancer.2021Cancer biotherapy & radiopharmaceuticals
  91. CDH1 Gene rs1801552 C/T Polymorphism Increases Susceptibility to Esophageal Squamous Cell Carcinoma but Not to Gastric Cardiac Adenocarcinoma.2021Cancer investigation
  92. Role of sympathetic and parasympathetic nerves in the development of gastric cancer through antagonism.2021Chinese medical journal免费全文
  93. Long Non-coding RNA LINC01503 Promotes Gastric Cardia Adenocarcinoma Progression via miR-133a-5p/VIM Axis and EMT Process.2021Digestive diseases and sciences
  94. Up-regulation of KLF17 expression increases the sensitivity of gastric cancer to 5-fluorouracil.2021International journal of immunopathology and pharmacology免费全文
  95. Meta-analysis of the efficacy of Da Vinci robotic or laparoscopic distal subtotal gastrectomy in patients with gastric cancer.2021Medicine免费全文
  96. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.2021Medicine免费全文
  97. Circ-sirt1 inhibits growth and invasion of gastric cancer by sponging miR-132-3p/miR-212-3p and upregulating sirt1 expression.2021Neoplasma
  98. TTPAL promotes gastric tumorigenesis by directly targeting NNMT to activate PI3K/AKT signaling.2021Oncogene免费全文
  99. LIMK1 promotes peritoneal metastasis of gastric cancer and is a therapeutic target.2021Oncogene免费全文
  100. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.2021Pathology, research and practice
  101. Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2.2021Scientific reports免费全文
  102. Research Progress and Application Prospects of Long Noncoding RNAs in Gastric Neoplasms.2021Technology in cancer research & treatment免费全文
  103. Effect of KLF17 overexpression on epithelial-mesenchymal transition of gastric cancer cells.2021The Journal of international medical research免费全文
  104. Sevoflurane represses the migration and invasion of gastric cancer cells by regulating forkhead box protein 3.2021The Journal of international medical research免费全文
中文论文(未计入)7
  1. [Cancer burden in Hebei Province from 2011 to 2020].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Cancer incidence, mortality and trends among elderly in Hebei province, 2011-2020].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled tri2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgeryRCT
  5. [The clinical value of further accurate staging of pT2 gastric cancer based on the depth of invasion].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  6. [Surgery treatment and prognosis analysis of 129 small cell carcinoma of the esophagogastric junction].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [The effect of cancer nodules on survival prognosis of gastric cancer patients].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)52
  1. Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)正在招募NCT07289997牵头方II期2025-09 启动
  2. A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer状态不明NCT01836120牵头方II期2013-04 启动
  3. Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer状态不明NCT01757366牵头方II期2012-12 启动
  4. Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer状态不明NCT01718626牵头方II期2012-10 启动
  5. Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer正在招募NCT07849608牵头方(推断)2026-09 启动
  6. DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)正在招募NCT07401173牵头方(推断)2026-03 启动
  7. Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer正在招募NCT07124754牵头方(推断)2025-01 启动
  8. A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10即将招募NCT07304258牵头方(推断)II期2025-12 启动
  9. AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data邀请入组NCT06957678牵头方(推断)2025-01 启动
  10. Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients邀请入组NCT06947096牵头方(推断)2025-01 启动
  11. Diagnosis of Peritoneal Exfoliative Cytology-positive Gastric Cancer Based on Artificial Intelligence-driven Virtual Biopsy Technology已完成NCT06759467牵头方(推断)2024-01 启动
  12. Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT05728606牵头方(推断)不分期2023-01 启动
  13. Multimodal Model Predicts Recurrence已完成NCT06690268牵头方(推断)2022-01 启动
  14. Effect of CNSI vs. ICG in Lymph Node Tracing During Gastrectomy状态不明NCT05229874牵头方(推断)II期2022-01 启动
  15. Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells状态不明NCT02510469牵头方(推断)II/III期2015-07 启动
  16. Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer状态不明NCT02509806牵头方(推断)II/III期2015-07 启动
  17. Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study已完成NCT02555358牵头方(推断)II期2014-11 启动
  18. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  19. Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)正在招募NCT07401199研究中心2026-02 启动
  20. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma即将招募NCT07902596研究中心2026-10 启动
  21. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动
  22. Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer即将招募NCT07828899研究中心不分期2026-10 启动
  23. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer正在招募NCT07127822研究中心II期2025-12 启动
  24. A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer正在招募NCT07110571研究中心II期2025-08 启动
  25. A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma正在招募NCT07023315研究中心III期2025-08 启动
  26. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  27. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  28. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  29. Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis状态不明NCT06278064研究中心2024-02 启动
  30. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  31. Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction进行中,不再招募NCT06576921研究中心II期2024-11 启动
  32. Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis状态不明NCT06363123研究中心2024-03 启动
  33. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  34. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  35. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  36. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  37. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma已终止NCT04718402研究中心I期2021-03 启动
  38. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  39. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  40. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  41. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  42. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  43. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  44. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer进行中,不再招募NCT04208347研究中心II/III期2019-12 启动
  45. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer状态不明NCT04139135研究中心III期2019-12 启动
  46. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer已完成NCT04082364研究中心II/III期2019-09 启动
  47. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  48. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  49. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  50. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  51. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  52. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

石家庄有 1 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 0020242025: 112025

石家庄有 8 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
牵头的论文6
  1. Oncolytic virus therapy for osteosarcoma: mechanisms, opportunities, and challenges.2025Frontiers in immunology
  2. Machine learning for predicting the survival in osteosarcoma patients: Analysis based on American and Hebei Province cohort.2023Biomolecules & biomedicine
  3. Hub biomarkers in ultrasound-guided bladder cancer and osteosarcoma: Myosin light chain kinase and caldesmon.2023Medicine
  4. Interaction of basic diseases and low red blood cell count as critical murderer of wound infection after osteosarcoma resection: Wound infection after osteosarcoma resection.2022Medicine
  5. Outstanding prognostic value of novel ferroptosis-related genes in chemoresistance osteosarcoma patients.2022Scientific reports
  6. Tumor-associated macrophages in osteosarcoma.2021Journal of Zhejiang University. Science. B
早期论文(2016–2020 年)5
  1. Leptin acts on mesenchymal stem cells to promote chemoresistance in osteosarcoma cells.2020Aging
  2. Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.2020Analytical cellular pathology (Amsterdam)
  3. Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.2019Journal of orthopaedic surgery and research
  4. Expression of Leptin and Sirtuin-1 is associated with poor prognosis in patients with osteosarcoma.2016Pathology, research and practice
  5. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 1.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 4420232024: 1120242025: 002025

石家庄有 4 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科普外/肝胆胰外科
牵头的论文7
  1. Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.2024Therapeutic drug monitoring
  2. Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib.2023BMC gastroenterology
  3. A New Online Dynamic Nomogram: Construction and Validation of a Predictive Model for Distant Metastasis Risk and Prognosis in Patients with Gastrointestinal Stromal Tumors.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  4. Computed tomographic imaging features to differentiate gastric schwannomas from gastrointestinal stromal tumours: a matched case-control study.2023Scientific reports免费全文
  5. Computed tomography features of gastric leiomyoma versus gastric stromal tumor: a case-control study with propensity score matching.2023The Journal of international medical research免费全文
  6. Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST.2022BMC gastroenterology
  7. Application of radiomics in predicting the preoperative risk stratification of gastric stromal tumors.2022Diagnostic and interventional radiology (Ankara, Turkey)
中文论文(未计入)1
  1. [Treatment strategy of gastrointestinal stromal tumors in the background of COVID-19].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
早期论文(2016–2020 年)3
  1. Evaluation for therapeutic measures to small gastric stromal tumor: A retrospective study of 90 cases.2018Current problems in cancer
  2. The risk factors about prognosis of 142 GIST patients with recurrence or metastasis: A retrospective study of single centre in Northern China.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  3. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.2017Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  2. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

石家庄有 4 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

石家庄有 2 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题儿童EB病毒与感染诱因遗传与家族性
论文中的科室儿科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

石家庄有 3 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题胸腺与胸腺切除

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

石家庄有 5 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

石家庄有 8 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

河北医科大学第四医院

Fourth Hospital of Hebei Medical University

石家庄

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Fourth Hospital of Hebei Medical University; Fourth Affiliated Hospital of Hebei Medical University; Hebei Medical University Fourth Affiliated Hospital; Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital; Fourth Hospital of Hebei Medical University Cancer Institute; Tumor Hospital of Hebei

提出更正下载数据